Kirkby Melanie, Popatia Alyanna M, Lavoie Jessie R, Wang Lisheng
Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8M5, Canada.
Ottawa Institute of Systems Biology, University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8M5, Canada.
Cancers (Basel). 2023 Sep 24;15(19):4702. doi: 10.3390/cancers15194702.
Triple-negative breast cancer (TNBC) is considered one of the most aggressive forms of breast cancer with poor survival rates compared to other breast cancer subtypes. TNBC is characterized by the absence of the estrogen receptor alpha, progesterone receptor, and the human epidermal growth factor receptor 2, limiting those viable treatment options available to patients with other breast cancer subtypes. Furthermore, due to the particularly high heterogeneity of TNBC, conventional treatments such as chemotherapy are not universally effective, leading to drug resistance and intolerable side effects. Thus, there is a pressing need to discover new therapies beneficial to TNBC patients. This review highlights current findings regarding the roles of three steroid hormone receptors, estrogen receptor beta, the androgen receptor, and the glucocorticoid receptor, in the progression of TNBC. In addition, we discussed several ongoing and completed clinical trials targeting these hormone receptors in TNBC patients.
三阴性乳腺癌（TNBC）被认为是最具侵袭性的乳腺癌形式之一，与其他乳腺癌亚型相比，生存率较低。TNBC的特征是缺乏雌激素受体α、孕激素受体和人表皮生长因子受体2，这限制了其他乳腺癌亚型患者可采用的可行治疗方案。此外，由于TNBC具有特别高的异质性，化疗等传统治疗方法并非普遍有效，会导致耐药性和难以忍受的副作用。因此，迫切需要发现对TNBC患者有益的新疗法。本综述重点介绍了关于三种类固醇激素受体，即雌激素受体β、雄激素受体和糖皮质激素受体在TNBC进展中的作用的当前研究结果。此外，我们还讨论了针对TNBC患者这些激素受体的几项正在进行和已完成的临床试验。
